Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA CAR-T in Relapsed and Refractory Multiple Myeloma
NCT05150522Phase 2Unknown
- Sponsor
- Shenzhen University General Hospital
- Start
- Jul 2021
- Primary completion
- Jul 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BCMA CAR-T cells in multiple myeloma (MM), sponsored by Shenzhen University General Hospital. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
BCMA CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05150522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05150522.